Stockreport

Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis [Yahoo! Finance]

Halozyme Therapeutics, Inc.  (HALO) 
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: halozyme.com/investors/default.aspx
PDF SAN DIEGO Sept. 13, 2024 "We are pleased that the subcutaneous formulation of OCREVUS, OCREVUS ZUNOVO, which contains our ENHANZE drug delivery technology, is now app [Read more]